sur POXEL (EPA:POXEL)
Key Scientific Presentations on Imeglimin at ADA 2025
POXEL SA, a clinical stage biopharmaceutical company, announced five presentations on the therapeutic potential of Imeglimin at the 85th Scientific Sessions of the American Diabetes Association in Chicago. These presentations are expected to highlight Imeglimin, marketed as TWYMEEG® in Japan, particularly in its role in addressing type 2 diabetes and related conditions.
The presentations cover various topics, such as its impact on inflammation and fibrosis in diabetic kidney disease and its efficacy on insulin sensitivity alongside Metformin. The studies are supported by Sumitomo Pharma and feature contributions from prominent Japanese diabetes experts.
CEO Thomas Kuhn expressed satisfaction with the scientific community's enthusiasm for TWYMEEG® as a potent treatment option for diabetic patients.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de POXEL